Reuters logo
BRIEF-Ablynx initiates the phase IIb "respire" study of anti-rsv nanobody
January 11, 2017 / 4:59 PM / 10 months ago

BRIEF-Ablynx initiates the phase IIb "respire" study of anti-rsv nanobody

Jan 11 (Reuters) - Ablynx NV :

* Ablynx initiates the phase IIB “respire” study of its wholly-owned, first-in-class, inhaled anti-rsv nanobody, ALX-0171, for the treatment of RSV infections in hospitalised infants

* ALX-0171 is a first-in-class inhaled nanobody developed for treatment of RSV infections

* ALX-0171 was safe and well tolerated in a phase IIa study in hospitalised infants with a RSV infection

* Topline results from this phase IIb study of inhaled ALX-0171 are expected in second half of 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below